Levofloxacin Inhalation Solution for the Treatment of Chronic Pseudomonas Aeruginosa Infection Among Patients with Cystic Fibrosis
Document Type
Article
Publication Date
2-2015
Find in a Library
Abstract
Chronic pulmonary infections are common among patients with cystic fibrosis. By 10 years of age, Pseudomonas aeruginosa is the predominant pathogen. Inhaled levofloxacin solution (MP-376) is a promising new therapy that exhibits rapid antibacterial activity and excellent biofilm penetration against P. aeruginosa. In the largest trial to date, 151 patients were randomized to receive MP-376 or placebo. At the end of the 28-day treatment period, patients who received MP-376 had decreased P. aeruginosa density in sputum, improved lung function parameters and improved respiratory symptoms. MP-376 also appeared to be safe and well tolerated. The results of two recently completed Phase III trials have not yet been released; however, these data will be critical in determining whether MP-376 is a safe and effective maintenance therapy for chronic pulmonary P. aeruginosa infections among patients with cystic fibrosis.
Repository Citation
Stockmann, C.,
Hillyard, B.,
Ampofo, K.,
Spigarelli, M. G.,
& Sherwin, C. M.
(2015). Levofloxacin Inhalation Solution for the Treatment of Chronic Pseudomonas Aeruginosa Infection Among Patients with Cystic Fibrosis. Expert Review of Respiratory Medicine, 9 (1), 13-22.
https://corescholar.libraries.wright.edu/pediatrics/244
DOI
10.1586/17476348.2015.986469
